Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

QUOTED. Martha Shadan.

Executive Summary

Medtech Insight spoke what Martha Shadan, CEO of Miach Orthopaedics, about the company’s marketing efforts for its FDA-cleared BEAR implant for treating anterior cruciate ligament (ACL) tears. See what Shadan said about it here.

“We are the first to clinically demonstrate that we can restore the patient's own ACL rather than replacing it. All the other technologies, even some that are emerging, they still rely on replacing the ACL, and we're the only one that restores the ACL for the broad majority of tear indications.” – Martha Shadan, CEO, Miach Orthopedics

 

Click here for a free trial of Medtech Insight

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT145289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel